McKesson Corp
MCK: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $378.00 | Bgbqck | Yjwfmjkz |
McKesson Enjoys Robust Sales of GLP-1s and Specialty Drugs, but at the Cost of Margin Loss
/s3.amazonaws.com/arc-authors/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
Business Strategy and Outlook
McKesson is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $240 billion in sales from its U.S. pharmaceutical segment in fiscal 2023, the company supplies roughly one third of the domestic drug distribution market. Its two close competitors are Cencora and Cardinal Health. Together, the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the U.S. market.